Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 621.80K | 611.00K | 621.10K | 615.20K | 1.73M |
| Total Depreciation and Amortization | 1.54M | 1.52M | 1.49M | 1.48M | 1.53M |
| Total Amortization of Deferred Charges | 222.00K | 218.20K | 196.30K | 194.40K | 215.80K |
| Total Other Non-Cash Items | 4.10M | 4.03M | 1.58M | 1.57M | -781.30K |
| Change in Net Operating Assets | -- | -- | 2.68M | 2.66M | -- |
| Cash from Operations | 6.49M | 6.38M | 6.57M | 6.51M | 2.69M |
| Capital Expenditure | -1.60M | -1.57M | -833.80K | -825.80K | -780.20K |
| Sale of Property, Plant, and Equipment | -- | -- | 16.40K | 16.20K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -88.20K | -86.60K | 98.30K | 97.40K | 589.60K |
| Cash from Investing | -1.69M | -1.66M | -719.10K | -712.20K | -190.60K |
| Total Debt Issued | 47.54M | 47.54M | 116.02M | 116.02M | 78.85M |
| Total Debt Repaid | -85.38M | -85.38M | -122.22M | -122.22M | -94.59M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.33M | -2.33M | -3.65M | -3.65M | -3.36M |
| Cash from Financing | -5.90M | -5.80M | -1.39M | -1.38M | -2.64M |
| Foreign Exchange rate Adjustments | -200.00K | -196.50K | -35.90K | -35.60K | -10.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.30M | -1.28M | 4.42M | 4.38M | -148.10K |